RIYADH, May 16, 2017 — King & Spalding (in association with The Law Office of Mohammed Al-Ammar) advised Kuwait-based Gulf Investment Corporation in its acquisition of a minority stake in Sudair Pharmaceutical Company in Saudi Arabia. Sudair Pharma is developing Sudair Specialized Pharmaceutical Complex in the Sudair Industrial City for manufacturing of high-end generic drugs for cancer treatment.
The King & Spalding team on the matter was led by partners Nabil Issa and Simon Rahimzada, associate Melissa Chan as well as counsel Mohammad Al Ammar and associates Faris Al Louzi and Bader Al-Ammar.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,000 lawyers in 19 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.